{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:36:50Z","timestamp":1786365410223,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shandong Pharmaceutical Association Special Scientific Research and Academic Activity Project","award":["yyyx2021qn-13"],"award-info":[{"award-number":["yyyx2021qn-13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11096-022-01472-x","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T08:04:02Z","timestamp":1664525042000},"page":"1351-1360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system"],"prefix":"10.1007","volume":"44","author":[{"given":"Jiao-Jiao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Chen","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-9868","authenticated-orcid":false,"given":"Quan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"issue":"1","key":"1472_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkx349","volume":"73","author":"M Heidary","year":"2018","unstructured":"Heidary M, Khosravi AD, Khoshnood S, et al. Daptomycin. J Antimicrob Chemother. 2018;73(1):1\u201311.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1472_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1128\/CMR.00030-13","volume":"26","author":"RM Humphries","year":"2013","unstructured":"Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013;26(4):759\u201380.","journal-title":"Clin Microbiol Rev"},{"issue":"24","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"6253","DOI":"10.1016\/j.bmc.2016.05.052","volume":"24","author":"SD Taylor","year":"2016","unstructured":"Taylor SD, Palmer M. The action mechanism of daptomycin. Bioorg Med Chem. 2016;24(24):6253\u201368.","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"1472_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/nrd1258","volume":"2","author":"P Kirkpatrick","year":"2003","unstructured":"Kirkpatrick P, Raja A, LaBonte J, et al. Daptomycin. Nat Rev Drug Discov. 2003;2(12):943\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1472_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653\u201365.","journal-title":"N Engl J Med"},{"issue":"5","key":"1472_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ijantimicag.2014.01.018","volume":"43","author":"HS Sader","year":"2014","unstructured":"Sader HS, Farrell DJ, Flamm RK, et al. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005\u20132012). Int J Antimicrob Agents. 2014;43(5):465\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"1472_CR7","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1086\/533441","volume":"46","author":"PE Pertel","year":"2008","unstructured":"Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis. 2008;46(8):1142\u201351.","journal-title":"Clin Infect Dis"},{"key":"1472_CR8","doi-asserted-by":"crossref","unstructured":"Ye Y, Xia Z, Zhang D, et al. Multifunctional Pharmaceutical Effects of the Antibiotic Daptomycin. Biomed Res Int. 2019;20198609218.","DOI":"10.1155\/2019\/8609218"},{"issue":"5","key":"1472_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1345\/aph.1K579","volume":"42","author":"G Abraham","year":"2008","unstructured":"Abraham G, Finkelberg D, Spooner LM. Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis. Ann Pharmacother. 2008;42(5):719\u201321.","journal-title":"Ann Pharmacother"},{"issue":"8","key":"1472_CR10","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1128\/AAC.03157-14","volume":"58","author":"N Bohm","year":"2014","unstructured":"Bohm N, Makowski C, Machado M, et al. Case report and cohort analysis of drug-induced liver injury associated with daptomycin. Antimicrob Agents Chemother. 2014;58(8):4902\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1472_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/INF.0000000000001926","volume":"37","author":"AC Arrieta","year":"2018","unstructured":"Arrieta AC, Bradley JS, Popejoy MW, et al. Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with staphylococcal bacteremia. Pediatr Infect Dis J. 2018;37(9):893\u2013900.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"1472_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/jac\/dkt512","volume":"69","author":"NK Shrestha","year":"2014","unstructured":"Shrestha NK, Mason P, Gordon SM, et al. Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study. J Antimicrob Chemother. 2014;69(5):1407\u201315.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1472_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ijantimicag.2012.12.008","volume":"41","author":"S Rege","year":"2013","unstructured":"Rege S, Mohr J, Lamp KC, et al. Safety of daptomycin in patients completing more than 14 days of therapy: results from the cubicin \u00ae Outcomes Registry and experience. Int J Antimicrob Agents. 2013;41(5):421\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"1472_CR14","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1093\/jac\/dku277","volume":"69","author":"W He","year":"2014","unstructured":"He W, Zhang Y, Chen H, et al. Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials. J Antimicrob Chemother. 2014;69(12):3181\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1472_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/11597460-000000000-00000","volume":"35","author":"PW Kim","year":"2012","unstructured":"Kim PW, Sorbello AF, Wassel RT, et al. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf. 2012;35(6):447\u201357.","journal-title":"Drug Saf"},{"issue":"3","key":"1472_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/0897190015625403","volume":"29","author":"Y Mo","year":"2016","unstructured":"Mo Y, Nehring F, Jung AH, et al. Possible hepatotoxicity associated with daptomycin: a case report and literature review. J Pharm Pract. 2016;29(3):253\u20136.","journal-title":"J Pharm Pract"},{"issue":"6","key":"1472_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/cid\/civ444","volume":"61","author":"NS Britt","year":"2015","unstructured":"Britt NS, Potter EM, Patel N, et al. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients. Clin Infect Dis. 2015;61(6):871\u20138.","journal-title":"Clin Infect Dis"},{"issue":"11\u201312","key":"1472_CR18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1024\/0040-5930\/a000746","volume":"72","author":"M Sch\u00e4ublin","year":"2015","unstructured":"Sch\u00e4ublin M. Pharmacovigiance: the spontaneous reporting system in Switzerland. Ther Umsch. 2015;72(11\u201312):743\u20138.","journal-title":"Ther Umsch"},{"issue":"5","key":"1472_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/pds.3378","volume":"22","author":"T Yamada","year":"2013","unstructured":"Yamada T, Watanabe Y, Kusama M, et al. Factors associated with spontaneous reporting of adverse drug reactions in Japan. Pharmacoepidemiol Drug Saf. 2013;22(5):468\u201376.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"1472_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pds.1796","volume":"18","author":"YS Shin","year":"2009","unstructured":"Shin YS, Lee YW, Choi YH, et al. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers. Pharmacoepidemiol Drug Saf. 2009;18(10):910\u20135.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1472_CR21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"issue":"11","key":"1472_CR22","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/14740338.2021.1956461","volume":"20","author":"M Gatti","year":"2021","unstructured":"Gatti M, Fusaroli M, Raschi E, et al. Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. Expert Opin Drug Saf. 2021;20(11):1421\u201331.","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"1472_CR23","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Xiao K, Ottaviani S, et al. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020;19(11):1505\u201311.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1472_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1574886313666181026100000","volume":"14","author":"V Subeesh","year":"2019","unstructured":"Subeesh V, Maheswari E, Singh H, et al. Novel adverse events of iloperidone: a disproportionality analysis in US food and drug administration adverse event reporting system (FAERS) database. Curr Drug Saf. 2019;14(1):21\u20136.","journal-title":"Curr Drug Saf"},{"issue":"2","key":"1472_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/YIC.0000000000000247","volume":"34","author":"U Lertxundi","year":"2019","unstructured":"Lertxundi U, Erezuma I, Hernandez R, et al. Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance). Int Clin Psychopharmacol. 2019;34(2):89\u201392.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"1472_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11096-020-01018-z","volume":"42","author":"R Neha","year":"2020","unstructured":"Neha R, Beulah E, Anusha B, et al. Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals. Int J Clin Pharm. 2020;42(2):721\u20137.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"1472_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7150\/ijms.7967","volume":"11","author":"T Sakaeda","year":"2014","unstructured":"Sakaeda T, Kadoyama K, Minami K, et al. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int J Med Sci. 2014;11(5):461\u20135.","journal-title":"Int J Med Sci"},{"key":"1472_CR28","doi-asserted-by":"crossref","unstructured":"Xu R, Wang Q. Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection. BMC Bioinformatics. 2014;1517.","DOI":"10.1186\/1471-2105-15-17"},{"issue":"2","key":"1472_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1365-2125.2003.01968.x","volume":"57","author":"AM Wilson","year":"2004","unstructured":"Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol. 2004;57(2):127\u201334.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1472_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","volume":"26","author":"M Hauben","year":"2003","unstructured":"Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2003;26(3):159\u201386.","journal-title":"Drug Saf"},{"issue":"11","key":"1472_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/pds.2014","volume":"19","author":"N Ooba","year":"2010","unstructured":"Ooba N, Kubota K. Selected control events and reporting odds ratio in signal detection methodology. Pharmacoepidemiol Drug Saf. 2010;19(11):1159\u201365.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1472_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1472_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"1472_CR34","first-page":"1798","volume":"17","author":"X Long","year":"2019","unstructured":"Long X, Gan X, Zeng X. Signal detection and evaluation of adverse reactions induced by regorafenib. Cent South Pharm. 2019;17(10):1798\u2013802.","journal-title":"Cent South Pharm"},{"issue":"10","key":"1472_CR35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40266-013-0114-8","volume":"30","author":"A Konychev","year":"2013","unstructured":"Konychev A, Heep M, Moritz RK, et al. Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial. Drugs Aging. 2013;30(10):829\u201336.","journal-title":"Drugs Aging"},{"issue":"10","key":"1472_CR36","doi-asserted-by":"publisher","first-page":"5726","DOI":"10.1128\/AAC.02910-14","volume":"58","author":"CM Bland","year":"2014","unstructured":"Bland CM, Bookstaver PB, Lu ZK, et al. Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors. Antimicrob Agents Chemother. 2014;58(10):5726\u201331.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1472_CR37","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","volume":"44","author":"FB Oleson Jr","year":"2000","unstructured":"Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44(11):2948\u201353.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1472_CR38","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","volume":"47","author":"BH Dvorchik","year":"2003","unstructured":"Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47(4):1318\u201323.","journal-title":"Antimicrob Agents Chemother"},{"issue":"04","key":"1472_CR39","first-page":"272","volume":"19","author":"D Wu","year":"2017","unstructured":"Wu D, Xing Y, Zhen J. Literature analysis of rhabdomyolysis induced by daptomycin. Adverse Drug React. 2017;19(04):272\u20136.","journal-title":"Adverse Drug React"},{"key":"1472_CR40","doi-asserted-by":"crossref","unstructured":"Chuma M, Nakamoto A, Bando T, et al. Association between statin use and daptomycin-related musculoskeletal adverse events: A mixed approach combining a meta-analysis and a disproportionality analysis. Clin Infect Dis. 2022.","DOI":"10.1093\/cid\/ciac128"},{"issue":"4","key":"1472_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.alit.2019.05.006","volume":"68","author":"Y Suzuki","year":"2019","unstructured":"Suzuki Y, Suda T. Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management. Allergol Int. 2019;68(4):413\u20139.","journal-title":"Allergol Int"},{"issue":"5","key":"1472_CR42","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2169\/internalmedicine.54.3397","volume":"54","author":"H Hagiya","year":"2015","unstructured":"Hagiya H, Hasegawa K, Asano K, et al. Myopathy and eosinophilic pneumonia coincidentally induced by treatment with daptomycin. Intern Med. 2015;54(5):525\u20139.","journal-title":"Intern Med"},{"issue":"12","key":"1472_CR43","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1086\/430352","volume":"191","author":"JA Silverman","year":"2005","unstructured":"Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191(12):2149\u201352.","journal-title":"J Infect Dis"},{"issue":"12","key":"1472_CR44","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673\u201381.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1472_CR45","doi-asserted-by":"publisher","first-page":"834","DOI":"10.7326\/0003-4819-136-11-200206040-00013","volume":"136","author":"N Safdar","year":"2002","unstructured":"Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834\u201344.","journal-title":"Ann Intern Med"},{"key":"1472_CR46","doi-asserted-by":"crossref","unstructured":"Ko\u0142pa M, Wa\u0142aszek M, Gniadek A, et al. Incidence, Microbiological Profile and Risk Factors of Healthcare-Associated Infections in Intensive Care Units: A 10 Year Observation in a Provincial Hospital in Southern Poland. Int J Environ Res Public Health. 2018;15(1).","DOI":"10.3390\/ijerph15010112"},{"issue":"5","key":"1472_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.3423","volume":"22","author":"M Kulldorff","year":"2013","unstructured":"Kulldorff M, Dashevsky I, Avery TR, et al. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol Drug Saf. 2013;22(5):517\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01472-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01472-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01472-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T20:03:14Z","timestamp":1670184194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01472-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01472-x","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"11 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}